175 related articles for article (PubMed ID: 22484811)
41. [Withdrawal of maintenance dialysis in a patient with diagnosed multiple myeloma and renal failure as a consequence of effective anti-tumor treatment].
Rosa J; Sydor A; Jurczyszyn A; Zabawa-Hołyś S; Nowak J; Czapkowicz-Gryszkiewicz L; Sułowicz W
Przegl Lek; 2010; 67(7):547-50. PubMed ID: 21387773
[TBL] [Abstract][Full Text] [Related]
42. Myeloma-related kidney disease.
Leung N; Nasr SH
Adv Chronic Kidney Dis; 2014 Jan; 21(1):36-47. PubMed ID: 24359985
[TBL] [Abstract][Full Text] [Related]
43. Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.
Yadav P; Hutchison CA; Basnayake K; Stringer S; Jesky M; Fifer L; Snell K; Pinney J; Drayson MT; Cook M; Cockwell P
Eur J Haematol; 2016 Jun; 96(6):610-7. PubMed ID: 26248588
[TBL] [Abstract][Full Text] [Related]
44. Coexistence of myeloma cast nephropathy, light chain deposition disease, and nonamyloid fibrils in a patient with multiple myeloma.
Qian Q; Leung N; Theis JD; Dogan A; Sethi S
Am J Kidney Dis; 2010 Nov; 56(5):971-6. PubMed ID: 20870327
[TBL] [Abstract][Full Text] [Related]
45. Myeloma kidney cast nephropathy in a rat model of multiple myeloma.
Smolens P; Venkatachalam M; Stein JH
Kidney Int; 1983 Aug; 24(2):192-204. PubMed ID: 6415338
[TBL] [Abstract][Full Text] [Related]
46. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains.
Leung N; Gertz MA; Zeldenrust SR; Rajkumar SV; Dispenzieri A; Fervenza FC; Kumar S; Lacy MQ; Lust JA; Greipp PR; Witzig TE; Hayman SR; Russell SJ; Kyle RA; Winters JL
Kidney Int; 2008 Jun; 73(11):1282-8. PubMed ID: 18385667
[TBL] [Abstract][Full Text] [Related]
47. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
[TBL] [Abstract][Full Text] [Related]
48. Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges.
Menè P; Stoppacciaro A; Lai S; Festuccia F
Int J Nephrol Renovasc Dis; 2022; 15():173-183. PubMed ID: 35592304
[TBL] [Abstract][Full Text] [Related]
49. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care.
Hutchison CA; Harding S; Mead G; Goehl H; Storr M; Bradwell A; Cockwell P
Artif Organs; 2008 Dec; 32(12):910-7. PubMed ID: 19133018
[TBL] [Abstract][Full Text] [Related]
50. Crystals in myeloma cast nephropathy.
Lin ZS; Zhou FD
QJM; 2021 Dec; 114(10):753-754. PubMed ID: 34264348
[No Abstract] [Full Text] [Related]
51. Plasmapheresis in myeloma cast nephropathy.
Chapdelaine I; Madore F
Clin Nephrol; 2013 Jan; 79(1):72-7. PubMed ID: 23249872
[TBL] [Abstract][Full Text] [Related]
52. Novel approaches for reducing free light chains in patients with myeloma kidney.
Hutchison CA; Bladé J; Cockwell P; Cook M; Drayson M; Fermand JP; Kastritis E; Kyle R; Leung N; Pasquali S; Winearls C;
Nat Rev Nephrol; 2012 Feb; 8(4):234-43. PubMed ID: 22349488
[TBL] [Abstract][Full Text] [Related]
53. Cast nephropathy with acute renal failure treated with high cut-off haemodialysis in a patient with multiple myeloma.
Shum HP; Chan KC; Chow CC; Kho BC; Yan WW
Hong Kong Med J; 2010 Dec; 16(6):489-92. PubMed ID: 21135429
[TBL] [Abstract][Full Text] [Related]
54. Recovery of kidney function following delayed use of Theralite™ dialyzer in a patient with myeloma cast nephropathy.
Dahal K; Shastri S; Narayanasami U; Bijol V; Rider K; Strom JA; Jaber BL
Clin Nephrol; 2013 Apr; 79(4):318-22. PubMed ID: 22541683
[TBL] [Abstract][Full Text] [Related]
55. Resolution of cast nephropathy following free light chain removal by haemodialysis in a patient with multiple myeloma: a case report.
Basnayake K; Hutchison C; Kamel D; Sheaff M; Ashman N; Cook M; Oakervee H; Bradwell A; Cockwell P
J Med Case Rep; 2008 Dec; 2():380. PubMed ID: 19068112
[TBL] [Abstract][Full Text] [Related]
56. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial.
Hutchison CA; Cook M; Heyne N; Weisel K; Billingham L; Bradwell A; Cockwell P
Trials; 2008 Sep; 9():55. PubMed ID: 18822172
[TBL] [Abstract][Full Text] [Related]
57. [Theralite and multiple myeloma].
Lachmanová J; Tesař V; Ryšavá R; Bartková M
Vnitr Lek; 2016; 62 Suppl 6():9-13. PubMed ID: 28124926
[TBL] [Abstract][Full Text] [Related]
58. Successful treatment of myeloma cast nephropathy using bortezomib-based chemotherapy plus selective plasma exchange.
Kawabe M; Yamamoto I; Katsuma A; Hayashi N; Komatsuzaki Y; Nakada Y; Shimizu A; Tanno Y; Ohkido I; Tsuboi N; Suzuki K; Shimada T; Ogasawara Y; Sugiyama K; Aiba K; Yokoo T
CEN Case Rep; 2016 Nov; 5(2):232-237. PubMed ID: 28508984
[TBL] [Abstract][Full Text] [Related]
59. Acute renal failure due to cast nephropathy in nonsecretory myeloma: a case report and review of the literature.
Kumar SK; Sohal PM; Kohli HS; Sud K; Gupta KL; Joshi K; Sakhuja V; Jha V
Int Urol Nephrol; 2005; 37(2):351-3. PubMed ID: 16142570
[TBL] [Abstract][Full Text] [Related]
60. Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: preliminary quantitative study.
Granger Vallée A; Chenine L; Leray-Moragues H; Patrier L; Cognot C; Cartron G; Cristol JP; Canaud B
Nephrol Dial Transplant; 2011 Nov; 26(11):3627-33. PubMed ID: 21508098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
